BMPs have been shown to have directly toxic effects on myeloma cells in vitro11–13; here we show that experimental inhibition of this signalling pathway in multiple myeloma models restored bone mass without any adverse effect on tumour bulk, revealing a novel role for BMP signalling in myeloma bone disease. Here, CLN5 is linked to plasma cell myeloma.